Diary - News
All news Erytech, positive results for GRASPA®, phase III
ERYTECH,the French biopharmaceutical company that develops innovative “tumor starvation” treatments for acute leukemia and other oncology indications with unmet medical needs, reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia.
